Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: Pooled analysis of three clinical trials

Researchers looked at the use of proton pump inhibitors and their effects on treatment outcomes in multiple myeloma patients undergoing daratumumab, lenalidomide, or bortezomib combination treatments. This study involved 1804 patients across three randomized-control trials, where one-third used PPIs at the beginning. Although the link with progression-free survival didn't reach statistical significance, PPI use was identified as a negative prognostic factor in MM patients across the trials and treatment arms.